TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03016130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
Study: NCT00887640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
Study: NCT03861221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBBCT
Description: To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
Study: NCT01553513

Intervention type: OTHER
Intervention: [18F]-FDG positron emission computed tomography
Description: Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest.

Intervention type: OTHER
Intervention: [18F]-FDG positron emission computed tomography
Description: Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest.

Intervention type: OTHER
Intervention: [18F]-FDG positron emission computed tomography
Description: Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest.
Study: NCT03190720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile community
Description: A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
Study: NCT01876238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PAT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: Pre-test and posttest surveys and questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Pre-test and posttest surveys and questionnaires
Study: NCT02496637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Awareness
Description: Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
Study: NCT00488033

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Angiography
Description: If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
Study: NCT01301742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: 1 tablet single dose BI 10773 in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil
Description: Gemfibrozil 600 mg bid for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: 1 tablet single dose BI 10773 in the morning
Study: NCT00395252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux®) and Gemcitabine
Description: Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion
Study: NCT00136747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Two capsules of Memantine twice daily for 12 days.
Study: NCT00175097

Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybeans and products made thereof
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybean flour and products made thereof
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybean milk
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet: Animal protein based diet
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
Study: NCT03730779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Patients will receive nocturnal normobaric hyperoxia therapy
Study: NCT02190279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F DCFBC
Description: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F DCFBC
Description: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F DCFBC
Description: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
Study: NCT03055741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg or 10mg, once a day, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg or 10mg, once a day, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5mg or 10mg, once a day, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP1401
Description: Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP1401
Description: Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administrated in two divided dosed a day for 24 weeks
Study: NCT01722955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-warmed fluids
Description: IV fluid will be stored at 41℃ set hot cabinet for 8hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperature fluids
Description: Room temperature fluid will be stored at ambient temperature
Study: NCT04021355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sodium supplementation
Description: Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sodium supplementation
Description: Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
Study: NCT00867048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All licensed antiretroviral medications
Description: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All licensed antiretroviral medications
Description: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
Study: NCT02872350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
Study: NCT00810628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Individual interviews and group discussion/training.
Study: NCT04690569

Intervention type: DIAGNOSTIC_TEST
Intervention: MeMed BV
Description: The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
Study: NCT00136747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02597023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Mitoquinone pill, 20 mg/day
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose cytarabine for induction
Description: 100 mg/m2/day Days 1-7
Study: NCT01675284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-301
Description: Inactivated H5N1 Influenza Virion Vaccine
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose cytarabine for induction
Description: 100 mg/m2/day Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously Day 1 or Days 1 and 4 of each cycle
Study: NCT01675284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-301
Description: Inactivated H5N1 Influenza Virion Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-301
Description: Inactivated H5N1 Influenza Virion Vaccine
Study: NCT03304340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation (FES)
Description: Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous nerve stimulation (TENS)
Description: Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation (SR)
Description: The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously Day 1 or Days 1 and 4 of each cycle
Study: NCT01553513

Intervention type: OTHER
Intervention: Serum biomarkers
Description: A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.

Intervention type: OTHER
Intervention: Serum biomarkers
Description: A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.

Intervention type: OTHER
Intervention: Serum biomarkers
Description: A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously Day 1 or Days 1 and 4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously Day 1 or Days 1 and 4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m2/day Days 1-3
Study: NCT03304340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation (SR)
Description: The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation (SR)
Description: The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
Study: NCT02671682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m2/day Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose cytarabine for consolidation
Description: 3g/m2 on Days 1, 3, and 5 of each cycle
Study: NCT01553513

Intervention type: OTHER
Intervention: Serum biomarkers
Description: A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.
Study: NCT04226131

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Description: A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
Study: NCT02326584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose cytarabine for consolidation
Description: 3g/m2 on Days 1, 3, and 5 of each cycle
Study: NCT02597023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Mitoquinone pill, 20 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill with inert excipient, 1 time/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill with inert excipient, 1 time/day
Study: NCT03165136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine : 200 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo of hydroxychloroquine
Study: NCT04226131

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Description: A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.

Intervention type: OTHER
Group type: OTHER
Intervention: Disease Activity (DAS-28) Assessment
Description: Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
Study: NCT04237584

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide during Lead-in Period
Description: Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Study: NCT04226131

Intervention type: OTHER
Group type: OTHER
Intervention: Skeletal Muscle Mitochondrial Respiratory Capacity
Description: Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
Study: NCT03126084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of intravenous acetaminophen will be administered twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of intravenous acetaminophen will be administered twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of intravenous acetaminophen will be administered twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine+Glucose
Description: 15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine+Glucose
Description: 15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine+Glucose
Description: 15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
Study: NCT03126084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques